Artificial intelligence (AI) is a broad field covering many different disciplines and it can also have many applications when it comes to antibody discovery. AI can help with designing antibodies and drastically reduce the time and cost of antibody engineering processes such as affinity maturation. AI can help develop cross-binding antibodies against many different antigen populations, including viral mutant strains. AI can learn the hidden patterns of the viral evolutionary process and extrapolate antibody designs, accordingly.
Sino Biological and Ainnocence have joined forces to establish an AI-enabled platform for antibody affinity maturation. Powered by a self-evolving artificial intelligence engine, Ainnocence's SentinusAI® is revolutionizing affinity maturation processes. Combined with the high-throughput recombinant antibody development program at Sino Biological, top candidates can be expressed recombinantly at a lower cost and shorter lead time to generate affinity data with a high hit rate of 15%. In this webinar, Dr. Sumana Sundaramurthy will take us through the journey of antibody discovery and discuss the antibody discovery platforms and their approaches at Sino Biological.
Learning Objectives:
• Overview of antibody development and antibody affinity maturation
• Traditional approaches to antibody development and antibody affinity maturation
• AI-based antibody discovery service and its approach at Sino Biological
• Advantages of AI-based antibody discovery over traditional approaches
• Future of AI-based antibody discovery and its impact on the drug development pipeline
About the Speaker
Sumana Sundaramurthy is a Technical Account Manager at Sino Biological where she supports R&D projects for industry and academic clients. Prior to joining Sino Biological, Sumana completed her doctoral studies at SUNY Upstate Medical University. In addition to her academic pursuits, Sumana held various leadership positions supporting student life at Upstate and other professional organizations. She has also worked for a preclinical CRO and a few notable research groups at Loyola University, the University of Chicago, and Sanofi Pasteur.